JP7507161B2 - 治療薬としてのｃＧＡＳ活性の阻害剤 - Google Patents

治療薬としてのｃＧＡＳ活性の阻害剤 Download PDF

Info

Publication number
JP7507161B2
JP7507161B2 JP2021539166A JP2021539166A JP7507161B2 JP 7507161 B2 JP7507161 B2 JP 7507161B2 JP 2021539166 A JP2021539166 A JP 2021539166A JP 2021539166 A JP2021539166 A JP 2021539166A JP 7507161 B2 JP7507161 B2 JP 7507161B2
Authority
JP
Japan
Prior art keywords
pyrimidin
methylbenzofuro
carboxylic acid
pyrrolidine
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518148A5 (https=
JP2022518148A (ja
Inventor
ジー． ローリー，ロバート
クマール，ミーラー
ボクサー，マシュー
マロニー，デイビッド
ボイド，スーザン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BellBrook Labs LLC
Original Assignee
BellBrook Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BellBrook Labs LLC filed Critical BellBrook Labs LLC
Publication of JP2022518148A publication Critical patent/JP2022518148A/ja
Publication of JP2022518148A5 publication Critical patent/JP2022518148A5/ja
Application granted granted Critical
Publication of JP7507161B2 publication Critical patent/JP7507161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021539166A 2019-01-04 2020-01-03 治療薬としてのｃＧＡＳ活性の阻害剤 Active JP7507161B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788624P 2019-01-04 2019-01-04
US62/788,624 2019-01-04
PCT/US2020/012243 WO2020142729A1 (en) 2019-01-04 2020-01-03 Inhibitors of cgas activity as therapeutic agents

Publications (3)

Publication Number Publication Date
JP2022518148A JP2022518148A (ja) 2022-03-14
JP2022518148A5 JP2022518148A5 (https=) 2023-03-06
JP7507161B2 true JP7507161B2 (ja) 2024-06-27

Family

ID=72338800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539166A Active JP7507161B2 (ja) 2019-01-04 2020-01-03 治療薬としてのｃＧＡＳ活性の阻害剤

Country Status (8)

Country Link
US (1) US20220073532A1 (https=)
EP (1) EP3906241A4 (https=)
JP (1) JP7507161B2 (https=)
KR (1) KR20210112316A (https=)
CN (1) CN113302194A (https=)
AU (1) AU2020205114A1 (https=)
CA (1) CA3125625A1 (https=)
WO (1) WO2020142729A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021349249A1 (en) * 2020-09-24 2023-04-13 Ventus Therapeutics U.S., Inc. Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals
US20240174684A1 (en) * 2021-02-11 2024-05-30 Bellbrook Labs, Llc INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
CN117337291A (zh) * 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有C-连接环状取代基的吡啶衍生物
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025172882A1 (en) 2024-02-14 2025-08-21 Janssen Pharmaceutica Nv Substituted pyrrolidine-2-carboxylic acid derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519794A (ja) 2004-11-11 2008-06-12 アージェンタ・ディスカバリー・リミテッド ピリミジン化合物
JP2009508911A (ja) 2005-09-21 2009-03-05 セルゾーム（ユーケー）リミティッド 炎症疾患治療のためのピリミジン化合物
JP2009543775A (ja) 2006-07-11 2009-12-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のベンゾフロ−およびベンゾチエノピリミジン系モジュレーター
WO2013115167A1 (ja) 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
WO2019084271A1 (en) 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
KR20250065420A (ko) * 2015-12-25 2025-05-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519794A (ja) 2004-11-11 2008-06-12 アージェンタ・ディスカバリー・リミテッド ピリミジン化合物
JP2009508911A (ja) 2005-09-21 2009-03-05 セルゾーム（ユーケー）リミティッド 炎症疾患治療のためのピリミジン化合物
JP2009543775A (ja) 2006-07-11 2009-12-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のベンゾフロ−およびベンゾチエノピリミジン系モジュレーター
WO2013115167A1 (ja) 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
WO2019084271A1 (en) 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2010年，20，2516-2519
REGISTRY（STN）［online］，2009年，CAS 登録番号：1165797-10-3; 1165762-97-9; 1165540-16-8; 1100125-17-4; 848731-15-7; 844455-03-4

Also Published As

Publication number Publication date
US20220073532A1 (en) 2022-03-10
EP3906241A1 (en) 2021-11-10
EP3906241A4 (en) 2022-11-02
AU2020205114A1 (en) 2021-07-22
WO2020142729A1 (en) 2020-07-09
KR20210112316A (ko) 2021-09-14
JP2022518148A (ja) 2022-03-14
CA3125625A1 (en) 2020-07-09
CN113302194A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7507161B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
JP7507162B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
JP6901479B2 (ja) Ｃｘｃｒ２の阻害剤
KR101442585B1 (ko) 특정 치환된 아미드, 그의 제조 방법, 및 그의 사용 방법
TWI398439B (zh) 特定經取代醯胺、其製法及其用途
CN112969687B (zh) 作为α4β7整合素抑制剂的喹啉衍生物
JP6553236B2 (ja) Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド
EP2696682B1 (en) Mif inhibitors and their uses
JP7097875B2 (ja) Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物
TWI478923B (zh) 喹唑啉酮化合物及其用途
JP2008519843A (ja) 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
EA012605B1 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
JP2024506904A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤
TW201441193A (zh) 吡啶酮化合物
WO2024076677A2 (en) Imidazolyl-alkoxyquinolin-2-amines
JP2025528113A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤
CN121895236A (zh) 一种itk激酶选择性抑制剂及其应用
EA049416B1 (ru) Ингибиторы аутофагии на основе гетероариламинопиримидинамида и способы их применения

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240617